Literature DB >> 10830419

Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys.

S Palfi1, L Leventhal, C G Goetz, T Hantraye, B Z Roitberg, J Sramek, M Emborg, J H Kordower.   

Abstract

Delayed abnormal movements can be observed in patients with acute neurologic insult after a prolonged period of apparent neurologic stability. To reproduce such a secondary neurologic manifestation in primates, the present experiment investigated whether systemic administration of subacute 3-nitropropionic acid (3NP), a mitochondrial toxin, could induce abnormal movements that were delayed and progressive over time. Four Cebus apella monkeys received systemic 3NP injections until acute neurologic signs manifested. The monkeys were regularly video-recorded and rated for abnormal movements for up to 15 weeks after the cessation of 3NP treatment. Five to 6 weeks after the 3NP treatment, monkeys displayed a significant increase in dyskinesias compared with pretreatment conditions. Over time the chorea attenuated, whereas the dystonic movements increased in intensity and severity which was characterized by a delayed decrease of peak tangential velocity. The intensity of abnormal movements and extent of affected body regions observed in each monkey were consistent with the size of basal ganglia hypersignal as documented by T2 sequence on magnetic resonance imaging. Thus, more severe motor impairments were associated with large magnetic resonance image abnormalities. This novel primate model may be particularly useful for studying the structural changes underlying delayed and progressive manifestations of abnormal movements with the ultimate goal of facilitating the evaluation of novel therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10830419

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  13 in total

Review 1.  Convergent mechanisms in etiologically-diverse dystonias.

Authors:  Valerie B Thompson; H A Jinnah; Ellen J Hess
Journal:  Expert Opin Ther Targets       Date:  2011-12-03       Impact factor: 6.902

Review 2.  Secondary blepharospasm associated with structural lesions of the brain.

Authors:  M A Khooshnoodi; S A Factor; H A Jinnah
Journal:  J Neurol Sci       Date:  2013-06-06       Impact factor: 3.181

Review 3.  Dystonia as a network disorder: what is the role of the cerebellum?

Authors:  C N Prudente; E J Hess; H A Jinnah
Journal:  Neuroscience       Date:  2013-12-11       Impact factor: 3.590

Review 4.  Animal models of generalized dystonia.

Authors:  Robert S Raike; H A Jinnah; Ellen J Hess
Journal:  NeuroRx       Date:  2005-07

5.  The basal ganglia and cerebellum interact in the expression of dystonic movement.

Authors:  Vladimir K Neychev; Xueliang Fan; V I Mitev; Ellen J Hess; H A Jinnah
Journal:  Brain       Date:  2008-07-26       Impact factor: 13.501

Review 6.  Animal models for dystonia.

Authors:  Bethany K Wilson; Ellen J Hess
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

Review 7.  The focal dystonias: current views and challenges for future research.

Authors:  H A Jinnah; Alfredo Berardelli; Cynthia Comella; Giovanni Defazio; Mahlon R Delong; Stewart Factor; Wendy R Galpern; Mark Hallett; Christy L Ludlow; Joel S Perlmutter; Ami R Rosen
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

8.  Nonhuman Primate Models of Neurodegenerative Disorders.

Authors:  Marina E Emborg
Journal:  ILAR J       Date:  2017-12-01

Review 9.  Experimental therapeutics for dystonia.

Authors:  H A Jinnah; Ellen J Hess
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 10.  Convergent evidence for abnormal striatal synaptic plasticity in dystonia.

Authors:  David A Peterson; Terrence J Sejnowski; Howard Poizner
Journal:  Neurobiol Dis       Date:  2009-12-18       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.